How can artificial intelligence (AI) shape cancer diagnosis, treatment and life after cancer? And how can patient-researcher collaboration accelerate progress in oncology These questions were at the heart of two recent scientific events attended by Yann Bizien, our Patient Committee Manager: the SFMPP Congress and the SFC Congress.
AI in Oncology: From Diagnosis to Life After Cancer
At SFMPP, Yann explored how AI could influence three key milestones in an exceptional cancer survivor’s journey: diagnosis, treatment and life after cancer. He joined Cyril Sarauste de Menthière, representing Patients en Réseau, oncologist Dr. Manuel Rodrigues, philosopher Bernard Baertschi and oncologist Dr. Stanislas Quesada for a discussion on predictive and personalized medicine.
Patient-Researcher Collaboration to Advance Cancer Research
At SFC, Yann brought a patient perspective to scientific discussions, expressing his enthusiasm for upcoming discoveries and new technological opportunities in oncology. He also highlighted the importance of patient-researcher collaboration in shaping cancer research. Bringing together patients, clinicians and scientists helps ensure that research priorities reflect patients' experiences and needs.
Putting Patients at the Heart of Cancer Research
Patient involvement is an integral part of our research approach. Through our Patient Committee and the Rosalind Study, we work to bring patient experiences and perspectives closer to scientific research.
Stronger collaboration between patients, clinicians and researchers can help guide research priorities, inform scientific questions and accelerate progress toward new therapeutic discoveries. We are committed to contributing to this dialogue and advancing patient collaboration across the TechBio and oncology landscape.
Updated: November 10, 2026
